Yahoo! Finance: Biotechnology Industry News: Merrimack Reaches Patient Enrollment Goal in the Phase 3 NAPOLI-1 Study of MM-398 in Late Stage Pancreatic Cancer

Yahoo! Finance: Biotechnology Industry News The latest news on the Biotechnology industry from Yahoo! Finance

Subscribe to Bloomberg Businessweek Get Bloomberg Businessweek for 84% off what others pay on the newsstand - that's like getting 38 complimentary issues! Sign up today. From our sponsors

Merrimack Reaches Patient Enrollment Goal in the Phase 3 NAPOLI-1 Study of MM-398 in Late Stage Pancreatic Cancer Aug 28th 2013, 12:00 [GlobeNewswire] - CAMBRIDGE, Mass. -- Merrimack Pharmaceuticals, Inc. announced today that the enrollment goal has been reached in the NAPOLI-1 trial. NAPOLI-1 is a randomized Phase 3 study of MM-398, with or without 5-fluorouracil ...

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions